Compare AbCellera Biologics Inc (ABCL) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Best Buy Co Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Best Buy Co Inc trades at $78.01 (market cap $16.59B). The key difference: Best Buy Co Inc is far larger — about 7.1× AbCellera Biologics Inc's market cap, and Best Buy Co Inc pays a 4.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BBY | |
|---|---|---|
Market Cap | $2.35B | $16.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $84.00 |
52-Week Low | $2.78 | $55.52 |
Enterprise Value | $1.99B | $18.97B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Best Buy (BBY) trades at $78.72, up 0.94% with a bullish technical outlook and positive earnings momentum after beating estimates for three consecutive quarters. The company shows strong profitability with 39.1% ROE and attractive valuation metrics including a 14.44 P/E ratio. Recent leadership transition and strategic focus on higher-margin businesses like marketplace expansion and retail media provide growth catalysts.
The stock offers value with a 5.11% dividend yield and 5% upside to consensus price target of $82.18, though revenue declines and competitive pressures in consumer electronics remain key risks. Analyst sentiment is mixed with 34% buy ratings versus 53% hold, reflecting cautious optimism about the turnaround strategy under new CEO Jason Bonfig.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
